Renovaro Inc. is a biotechnology company focused on the development of innovative therapies and solutions aimed at addressing unmet medical needs
The company specializes in advanced research and development in the field of regenerative medicine, utilizing cutting-edge technologies to create treatments that promote healing and recovery for patients suffering from various conditions. Through its commitment to scientific excellence and collaboration, Renovaro seeks to transform the healthcare landscape by bringing groundbreaking therapies from the lab to the clinic, ultimately improving patient outcomes and enhancing quality of life.
Company Commits the First Tranche of Financing to Initiate the Integration of AI/ML Platform Technologies, Core Laboratory Capabilities and Business Development Efforts in Europe and the United States
Predictive receives first tranche of financing to initiate integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States
Wondering how the US markets performed one hour before the close of the markets on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Strategic Combination Aims to Accelerate Biomarker Identification, Enhance Drug Discovery, and Expand Precision Medicine Applications in Cancer and Beyond
LOS ANGELES, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQRENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announces that it has $15 million in additional equity committed at a price per share of $1.00 and one privately placed cash warrant exercisable at $1.50 with a one year term.
BALA CYNWYD, Pa., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Acquisition provides access to critical resources encompassing a biobank of more than 150,000 tumor specimens, 200,000 pathology slides and decades of longitudinal drug response data
- Combination creates immediate scientific synergies by harnessing complementary AI / ML platforms to improve patient outcomes across multiple cancer indications –
LOS ANGELES, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQRENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced that it has received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule, 5550(a)(2). The Company’s security will continue to be listed and traded on The Nasdaq Stock Market and this matter is now closed.
LOS ANGELES, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQRENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today issued a letter to shareholders from Chief Executive Officer David Weinstein.
AMSTERDAM, Oct. 17, 2024 (GLOBE NEWSWIRE) -- (NASDAQRENB) – RenovaroCube, a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid biopsies, is excited to announce the presentation of its latest research at the Molecular Analysis for Precision Oncology Congress – on October 16, 2024.
LOS ANGELES, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQRENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced a strategic restructuring and leadership transition of senior management and the Board of Directors to realign resources focused on the Company’s AI Platform, RenovaroCube for multi-cancer early detection and patient monitoring. The Board, with the support of a supermajority of shareholders, appointed David Weinstein as director and new CEO and four new directors – Maurice van Tilburg, Chairman, Douglas Calder, James A. McNulty CPA, and Mark A. Collins PhD.
